• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials
scientific articles

Immunologic Effects of Hydroxyurea in Sickle Cell Anemia

key information

source: Pediatrics

year: 2014

authors: Howard M. Lederman, Margaret A. Connolly, Ram Kalpatthi, Russell E. Ware, Winfred C. Wang, Lori Luchtman-Jones, Myron Waclawiw, Jonathan C. Goldsmith, Andrea Swift, James F. Casella

summary/abstract:

Background and Objective:
Susceptibility to encapsulated bacteria is well known in sickle cell disease (SCD). Hydroxyurea use is common in adults and children with SCD, but little is known about hydroxyurea’s effects on immune function in SCD. Because hydroxyurea inhibits ribonucleotide reductase, causing cell cycle arrest at the G1-S interface, we postulated that hydroxyurea might delay transition from naive to memory T cells, with inhibition of immunologic maturation and vaccine responses.

Methods:
T-cell subsets, naive and memory T cells, and antibody responses to pneumococcal and measles, mumps, and rubella vaccines were measured among participants in a multicenter, randomized, double-blind, placebo-controlled trial of hydroxyurea in infants and young children with SCD (BABY HUG).

Results:
Compared with placebo, hydroxyurea treatment resulted in significantly lower total lymphocyte, CD4, and memory T-cell counts; however, these numbers were still within the range of historical healthy controls. Antibody responses to pneumococcal vaccination were not affected, but a delay in achieving protective measles antibody levels occurred in the hydroxyurea group. Antibody levels to measles, mumps, and rubella showed no differences between groups at exit, indicating that effective immunization can be achieved despite hydroxyurea use.

Conclusions:
Hydroxyurea does not appear to have significant deleterious effects on the immune function of infants and children with SCD. Additional assessments of lymphocyte parameters of hydroxyurea-treated children may be warranted. No changes in current immunization schedules are recommended; however, for endemic disease or epidemics, adherence to accelerated immunization schedules for the measles, mumps, and rubella vaccine should be reinforced.

organization: Clinical Trials and Surveys Corp, USA; Children's Mercy Hospital, USA; Cincinnati Children's Hospital Medical Center, USA; St. Jude Children's Research Hospital, USA; Children's National Medical Center, USA; National Institutes of Health, USA; Johns Hopkins University School of Medicine, USA

DOI: 10.1542/peds.2014-0571

read more full text source